-
Je něco špatně v tomto záznamu ?
Comorbidity and medication in REM sleep behavior disorder: a multicenter case-control study
B. Frauscher, P. Jennum, YE. Ju, RB. Postuma, I. Arnulf, V. Cochen De Cock, Y. Dauvilliers, ML. Fantini, L. Ferini-Strambi, D. Gabelia, A. Iranzo, S. Leu-Semenescu, T. Mitterling, M. Miyamoto, T. Miyamoto, JY. Montplaisir, W. Oertel, A....
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, multicentrická studie, práce podpořená grantem
- MeSH
- aplikace inhalační MeSH
- deprese farmakoterapie epidemiologie MeSH
- glukokortikoidy terapeutické užití MeSH
- ischemická choroba srdeční epidemiologie MeSH
- kohortové studie MeSH
- komorbidita MeSH
- kouření epidemiologie MeSH
- lidé středního věku MeSH
- lidé MeSH
- porucha chování v REM spánku farmakoterapie epidemiologie MeSH
- průzkumy a dotazníky MeSH
- rizikové faktory MeSH
- selektivní inhibitory zpětného vychytávání serotoninu terapeutické užití MeSH
- senioři MeSH
- studie případů a kontrol MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
- práce podpořená grantem MeSH
OBJECTIVE: This controlled study investigated associations between comorbidity and medication in patients with polysomnographically confirmed idiopathic REM sleep behavior disorder (iRBD), using a large multicenter clinic-based cohort. METHODS: Data of a self-administered questionnaire on comorbidity and medication use of 318 patients with iRBD and 318 matched controls were analyzed. Comparisons between cases and controls were made using logistic regression analysis. RESULTS: Patients with iRBD were more likely to report depression (odds ratio [OR] 2.0, 95% confidence interval [CI] 1.3-2.9) and concomitant antidepressant use (OR 2.2, 95% CI 1.4-3.6). Subanalysis of antidepressant agents revealed that the increased use of antidepressants in iRBD was due to selective serotoninergic reuptake inhibitors (OR 3.6, 95% CI 1.8-7.0) and not due to other antidepressant classes. Patients with iRBD reported more lifetime antidepressant use than comorbid depression (antidepressant use: OR 1.9, 95% CI 1.1-3.3; depression: OR 1.6, 95% CI 1.0-2.5). Patients with iRBD reported more ischemic heart disease (OR 1.9, 95% CI 1.1-3.1). This association did not change substantially when adjusting for cardiovascular risk factors (OR 2.3, 95% CI 1.3-3.9). The use of inhaled glucocorticoids was higher in patients with iRBD compared to controls (OR 5.3, 95% CI 1.8-15.8), likely reflecting the higher smoking rate in iRBD (smoking: OR 15.3, 95% CI 2.0-118.8; nonsmoking: OR 2.4, 95% CI 0.4-13.2) and consequent pulmonary disease. CONCLUSIONS: This large study confirms the association between comorbid depression and antidepressant use in iRBD. In addition, there was an unexpected association of iRBD with ischemic heart disease that was not explained by cardiovascular risk factors.
Centre d'Études Avancées en Médecine du Sommeil Hôpital du Sacré Coeur de Montréal Canada
Danish Center for Sleep Medicine University of Copenhagen Denmark
Department of Neurology Dokkyo Medical University Koshigaya Hospital Saitama Japan
Department of Neurology Dokkyo Medical University School of Medicine Tochigi
Department of Neurology McGill University Montreal General Hospital Canada
Department of Neurology Saarland University Homburg Saar
Department of Neurology Washington University School of Medicine St Louis MO
From the Department of Neurology Innsbruck Medical University Austria
Hephata Klinik Schwalmstadt Treysa Germany
Neuroepidemiology Research Unit Research Institute of the McGill University Health Centre Montreal
Neurology Service Hospital Clinic de Barcelona IDIBAPS CIBERNED Spain
Philipps Universität Marburg Germany
Sleep Center Department of Cardiovascular and Neurological Sciences University of Cagliari Italy
Sleep Disorders Center Department of Neurosciences University of Turin Italy
Sleep Disorders Center Università Vita Salute San Raffaele Milan Italy
UFR Medecine EA 7280 University Clermont 1 France
Unit of Sleep Medicine National Institute of Neurology IRCCS C Mondino Foundation Pavia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14063711
- 003
- CZ-PrNML
- 005
- 20171030123835.0
- 007
- ta
- 008
- 140704s2014 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1212/WNL.0000000000000247 $2 doi
- 035 __
- $a (PubMed)24553425
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Frauscher, Birgit $u From the Department of Neurology (B.F., D.G., T.M., B.H.), Innsbruck Medical University, Austria; Danish Center for Sleep Medicine (P.J.), University of Copenhagen, Denmark; Department of Neurology (Y.-E.S.J.), Washington University School of Medicine, St Louis, MO; Department of Neurology (R.B.P.), McGill University, Montreal General Hospital, Canada; Unité des Pathologies du Sommeil (I.A., S.L.-S.), Hôpital Pitié-Salpêtrière, APHP, and Inserm U975-CRICM-Pierre and Marie Curie University, Paris; Sleep Unit (V.C.D.C., Y.D.), Department of Neurology, Hôpital Gui de Chauliac, Montpellier, INSERM U1061, Montpellier, France; Sleep Disorders Center (M.L.F.), Department of Neurosciences, University of Turin, Italy; UFR Medecine (M.L.F.), EA 7280, University Clermont 1, France; Sleep Disorders Center (L.F.-S., M.Z.), Università Vita-Salute San Raffaele, Milan, Italy; Neurology Service (A.I., J.S.), Hospital Clinic de Barcelona, IDIBAPS, CIBERNED, Spain; Department of Neurology (M.M.), Dokkyo Medical University School of Medicine, Tochigi; Department of Neurology (T.M.), Dokkyo Medical University Koshigaya Hospital, Saitama, Japan; Centre d'Études Avancées en Médecine du Sommeil (J.Y.M.), Hôpital du Sacré-Coeur de Montréal, Canada; Philipps-Universität (W.O., M.U.), Marburg, Germany; Neuroepidemiology Research Unit (A.P., C.W.), Research Institute of the McGill University Health Centre, Montreal; Canada; Unit of Sleep Medicine (P.P., M.T., R.M.), National Institute of Neurology IRCCS, C. Mondino Foundation, Pavia; Sleep Center (M.P.), Department of Cardiovascular and Neurological Sciences, University of Cagliari, Italy; Department of Neurology (K.S.), First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic; Department of Neurology (M.U.), Saarland University, Homburg/Saar; and Hephata Klinik (G.M.), Schwalmstadt-Treysa, Germany.
- 245 10
- $a Comorbidity and medication in REM sleep behavior disorder: a multicenter case-control study / $c B. Frauscher, P. Jennum, YE. Ju, RB. Postuma, I. Arnulf, V. Cochen De Cock, Y. Dauvilliers, ML. Fantini, L. Ferini-Strambi, D. Gabelia, A. Iranzo, S. Leu-Semenescu, T. Mitterling, M. Miyamoto, T. Miyamoto, JY. Montplaisir, W. Oertel, A. Pelletier, P. Prunetti, M. Puligheddu, J. Santamaria, K. Sonka, M. Unger, C. Wolfson, M. Zucconi, M. Terzaghi, B. Högl, G. Mayer, R. Manni,
- 520 9_
- $a OBJECTIVE: This controlled study investigated associations between comorbidity and medication in patients with polysomnographically confirmed idiopathic REM sleep behavior disorder (iRBD), using a large multicenter clinic-based cohort. METHODS: Data of a self-administered questionnaire on comorbidity and medication use of 318 patients with iRBD and 318 matched controls were analyzed. Comparisons between cases and controls were made using logistic regression analysis. RESULTS: Patients with iRBD were more likely to report depression (odds ratio [OR] 2.0, 95% confidence interval [CI] 1.3-2.9) and concomitant antidepressant use (OR 2.2, 95% CI 1.4-3.6). Subanalysis of antidepressant agents revealed that the increased use of antidepressants in iRBD was due to selective serotoninergic reuptake inhibitors (OR 3.6, 95% CI 1.8-7.0) and not due to other antidepressant classes. Patients with iRBD reported more lifetime antidepressant use than comorbid depression (antidepressant use: OR 1.9, 95% CI 1.1-3.3; depression: OR 1.6, 95% CI 1.0-2.5). Patients with iRBD reported more ischemic heart disease (OR 1.9, 95% CI 1.1-3.1). This association did not change substantially when adjusting for cardiovascular risk factors (OR 2.3, 95% CI 1.3-3.9). The use of inhaled glucocorticoids was higher in patients with iRBD compared to controls (OR 5.3, 95% CI 1.8-15.8), likely reflecting the higher smoking rate in iRBD (smoking: OR 15.3, 95% CI 2.0-118.8; nonsmoking: OR 2.4, 95% CI 0.4-13.2) and consequent pulmonary disease. CONCLUSIONS: This large study confirms the association between comorbid depression and antidepressant use in iRBD. In addition, there was an unexpected association of iRBD with ischemic heart disease that was not explained by cardiovascular risk factors.
- 650 _2
- $a aplikace inhalační $7 D000280
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a kohortové studie $7 D015331
- 650 _2
- $a komorbidita $7 D015897
- 650 _2
- $a deprese $x farmakoterapie $x epidemiologie $7 D003863
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a glukokortikoidy $x terapeutické užití $7 D005938
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a ischemická choroba srdeční $x epidemiologie $7 D017202
- 650 _2
- $a průzkumy a dotazníky $7 D011795
- 650 _2
- $a porucha chování v REM spánku $x farmakoterapie $x epidemiologie $7 D020187
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a selektivní inhibitory zpětného vychytávání serotoninu $x terapeutické užití $7 D017367
- 650 _2
- $a kouření $x epidemiologie $7 D012907
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Jennum, Poul
- 700 1_
- $a Ju, Yo-El S
- 700 1_
- $a Postuma, Ronald B
- 700 1_
- $a Arnulf, Isabelle $7 gn_A_00008768
- 700 1_
- $a Cochen De Cock, Valerie
- 700 1_
- $a Dauvilliers, Yves
- 700 1_
- $a Fantini, Maria L
- 700 1_
- $a Ferini-Strambi, Luigi, $d 1955- $7 xx0217963
- 700 1_
- $a Gabelia, David
- 700 1_
- $a Iranzo, Alex
- 700 1_
- $a Leu-Semenescu, Smaranda
- 700 1_
- $a Mitterling, Thomas
- 700 1_
- $a Miyamoto, Masayuki
- 700 1_
- $a Miyamoto, Tomoyuki
- 700 1_
- $a Montplaisir, Jacques Y
- 700 1_
- $a Oertel, Wolfgang
- 700 1_
- $a Pelletier, Amélie
- 700 1_
- $a Prunetti, Paolo
- 700 1_
- $a Puligheddu, Monica
- 700 1_
- $a Santamaria, Joan
- 700 1_
- $a Sonka, Karel
- 700 1_
- $a Unger, Marcus
- 700 1_
- $a Wolfson, Christina
- 700 1_
- $a Zucconi, Marco
- 700 1_
- $a Terzaghi, Michele
- 700 1_
- $a Högl, Birgit
- 700 1_
- $a Mayer, Geert
- 700 1_
- $a Manni, Raffaele
- 773 0_
- $w MED00003491 $t Neurology $x 1526-632X $g Roč. 82, č. 12 (2014), s. 1076-9
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/24553425 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140704 $b ABA008
- 991 __
- $a 20171030123924 $b ABA008
- 999 __
- $a ok $b bmc $g 1031195 $s 862443
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 82 $c 12 $d 1076-9 $i 1526-632X $m Neurology $n Neurology $x MED00003491
- LZP __
- $a Pubmed-20140704
